J Cancer 2018; 9(2):219-231. doi:10.7150/jca.22554 This issue


Break Breast Cancer Addiction by CRISPR/Cas9 Genome Editing

Haitao Yang1, MariaLynn Jaeger2, Averi Walker2, Daniel Wei3, Katie Leiker2, Tao Weitao2

1. Laboratory for Cancer Genome Editing, Zhuhai Lifecode Medical Technologies. Inc. Department of Prenatal Diagnosis, Huizhou 2nd Hospital for Children and Women, #101 University Road, Tangjiawan, Zhuhai, 518900, Guangdong, China;
2. College of Science and Mathematics, Southwest Baptist University, 1600 University Avenue, Bolivar, Missouri 65613, USA;
3. University of Texas at Dallas, 800 W Campbell Rd, Richardson, TX 75080, USA.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Yang H, Jaeger M, Walker A, Wei D, Leiker K, Weitao T. Break Breast Cancer Addiction by CRISPR/Cas9 Genome Editing. J Cancer 2018; 9(2):219-231. doi:10.7150/jca.22554. Available from https://www.jcancer.org/v09p0219.htm

File import instruction


Breast cancer is the leading diagnosed cancer for women globally. Evolution of breast cancer in tumorigenesis, metastasis and treatment resistance appears to be driven by the aberrant gene expression and protein degradation encoded by the cancer genomes. The uncontrolled cancer growth relies on these cellular events, thus constituting the cancerous programs and rendering the addiction towards them. These programs are likely the potential anticancer biomarkers for Personalized Medicine of breast cancer. This review intends to delineate the impact of the CRSPR/Cas-mediated genome editing in identification and validation of these anticancer biomarkers. It reviews the progress in three aspects of CRISPR/Cas9-mediated editing of the breast cancer genomes: Somatic genome editing, transcription and protein degradation addictions.

Keywords: Breast cancer, tumorigenesis, metastasis, mutations, transcription, protein degradation, anticancer resistance, CRISPR/Cas9, genome.